FIELD: medicine.
SUBSTANCE: invention relates to a method for treating tumor cells or prophylaxis, or suppressing the growth, spread, or metastasis of a tumor by administering to a patient a peptide, peptidomimetic or an amino acid derivative having a net positive charge of at least +2 at pH 7.0 and containing disubstituted β-amino acid, each of the substituting groups in β-amino acid, which may be the same or different, includes at least 7 non-hydrogen atoms, is lipophilic and includes at least one cyclic group, moreover, one or more cyclic groups in the substituting group may be linked or fused with one or more cyclic groups in another substituting group, and when cyclic groups are fused in this way, the combined total number of non-hydrogen atoms for these two substituting groups is at least 12.
EFFECT: therapeutic peptides are proposed.
10 cl, 4 dwg, 10 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC PEPTIDES | 2010 |
|
RU2548905C2 |
ANTIBIOTIC PEPTIDES | 2008 |
|
RU2472805C2 |
RGD-CONTAINING PEPTIDOMIMETICS AND THEIR APPLICATION | 2009 |
|
RU2519736C2 |
NONAPEPTIDE WITH ANTITUMOUR ACTIVITY | 2009 |
|
RU2503685C2 |
PEPTIDES INHIBITING NEURON EXOCYTOSIS | 2007 |
|
RU2461568C2 |
CYCLIC ANTIMICROBIAL PEPTIDES | 2006 |
|
RU2463308C2 |
CONTRAST AGENT AIMED AT UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR | 2005 |
|
RU2394837C2 |
ANTIMICROBIAL PEPTIDES | 2005 |
|
RU2392962C2 |
PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2582916C2 |
HOMODETIC CYCLIC PEPTIDES SPECIFICALLY ACTING ON α4β7 INTEGRIN | 2018 |
|
RU2773443C2 |
Authors
Dates
2019-01-10—Published
2010-11-02—Filed